SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. announced today that its Ventiv Commercial Services (VCS) group has signed a sales and marketing partnership with Connetics Corporation . A specialized sales team of 50 sales representatives and supporting sales management will be established to focus on sales and education of Connetics' top dermatological products Evoclin(R), Luxiq(R) and OLUX(R) to a targeted group of primary care physicians and pediatricians. Connetics will utilize a full suite of Ventiv's sales and marketing services including training, fleet, sales force automation, and sample accountability, and will enlist Ventiv's PROMOTECH division for sample and material distribution.
Greg Vontz, President and Chief Operating Officer of Connetics, said, "Our focus will be to inform, sample and provide patient educational materials to select PCP's and pediatricians who are prescribing our products on the correct usage of our products, and to demonstrate the value of our brands to physicians both inside and outside the dermatology area. Our partnership with Ventiv allows us to execute our plan by establishing a specialized sales force experienced in this area."
Terry Herring, President and COO of Ventiv Commercial Services said, "We recently announced that Ventiv has added 245 sales representatives across six new sales team clients so far in 2005 and are delighted that Connetics is among those clients who have selected us to support their commercialization efforts. Connetics has enjoyed prescription growth among the targeted PCPs, and we intend to use our dermatology expertise to help continue this positive trend."
Overview of Products to be sold by Ventiv
OLUX (clobetasol propionate) Foam, 0.05% is a super-high-potency corticosteroid, delivered in Connetics' proprietary VersaFoam-HF(TM) vehicle, and is indicated for the short-term topical treatment of mild to moderate plaque-type psoriasis of scalp and non-scalp regions. OLUX absorbs quickly after it is applied to the skin, and has been proven to deliver rapid and effective results. OLUX is available in 50g and 100g trade unit sizes.
Luxiq (betamethasone valerate) Foam, 0.12%, is a mid-potency corticosteroid, delivered in Connetics' proprietary VersaFoam-HF vehicle, and is indicated for the treatment of the inflammatory and pruritic manifestations of corticosteroid-responsive scalp dermatoses. Luxiq is available in 50g, 100g and 150g trade unit sizes.
Evoclin (clindamycin) Foam, 1% is a once-a-day topical foam for the treatment of acne vulgaris. Evoclin is delivered in VersaFoam-HF and is available in 50g and 100g trade unit sizes.
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin) Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne, and Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis. Connetics' product formulations aim to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit http://www.connetics.com/.
About Ventiv Health
Ventiv Health, Inc. is the leading provider of late-stage clinical, sales, marketing and compliance solutions to pharmaceutical and biotech companies. Ventiv is a multi-disciplinary company with a singular focus on providing excellence in customized solutions across the full spectrum of services combining both integrated and independent programs. Ventiv's approximately 4,000 employees support over 75 client organizations, including the world's Top 20 pharmaceuticals companies as well as emerging and specialty biotech leaders. For more information on Ventiv Health, visit http://www.ventiv.com/ .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.